8-K filing — SurgePays, Inc. (SURG)
Filed: 2026-09-16 AccNo: 0001493152-26-042938 Size: 205 KB Item 4.01: Changes in Registrant's Certifying Accountant
Stocks · News reference
SurgePays stock plunges 30% after hours following Q2 results and liquidity concerns.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-09-16 AccNo: 0001493152-26-042938 Size: 205 KB Item 4.01: Changes in Registrant's Certifying Accountant
Ascendiant Capital analyst Edward Woo maintains Surgepays (NASDAQ:SURG) with a Buy and raises the price target from $3.5 to $3.75.
Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
RH shares jumped 8.2% premarket after EPS beat estimates despite a revenue miss; Oracle and others gained, while OPTT and ZUMZ fell.